Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Preferred Stock Liabilities (2019 - 2020)

Nurix Therapeutics (NRIX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $168.1 million as the latest value for Q2 2020.

  • Quarterly Preferred Stock Liabilities rose 248.81% to $168.1 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $168.1 million through May 2020, up 248.81% year-over-year, with the annual reading at $48.2 million for FY2019, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q2 2020 was $168.1 million at Nurix Therapeutics, up from $48.2 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $168.1 million in Q2 2020, with the low at $48.2 million in Q2 2019.